STRS Ohio’s CRISPR Therapeutics CRSP Stock Holding History

STRS Ohio’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Buy	19,323 +1,400	+8%	+$73.8K	﹤0.01%	712
2026 Q1	$853K	Sell	17,923 -5,600	-24%	-$295K	﹤0.01%	766
2025 Q4	$1.23M	Hold	23,523	–	–	﹤0.01%	646
2025 Q3	$1.52M	Buy	23,523 +18,123	+336%	+$1.04M	0.01%	595
2025 Q2	$263K	Buy	+5,400	New	+$209K	﹤0.01%	1561
2021 Q3	–	Sell	-11,642	Closed	-$1.88M	–	2256
2021 Q2	$1.88M	Hold	11,642	–	–	0.01%	785
2021 Q1	$1.42M	Hold	11,642	–	–	0.01%	916
2020 Q4	$1.78M	Hold	11,642	–	–	0.01%	746
2020 Q3	$973K	Buy	+11,642	New	+$1.03M	﹤0.01%	944
2019 Q3	–	Sell	-32,406	Closed	-$1.53M	–	2080
2019 Q2	$1.53M	Hold	32,406	–	–	0.01%	701
2019 Q1	$1.16M	Hold	32,406	–	–	0.01%	769
2018 Q4	$925K	Buy	+32,406	New	+$1.13M	﹤0.01%	813

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

STRS Ohio's CRSP Position: Q2 2026 in Review

STRS Ohio increased its CRISPR Therapeutics (CRSP) stake by 7.8% in Q2 2026, buying an estimated $73.8K and bringing the position to 19,323 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #712.

STRS Ohio first reported a position in CRSP in Q4 2018 and has held it in 12 quarters since. The position peaked at $1.88M in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

STRS Ohio held 19,323 shares of CRISPR Therapeutics worth $1.05M as of Q2 2026.
STRS Ohio bought 1,400 CRISPR Therapeutics shares in Q2 2026, an estimated $73.8K.
CRISPR Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #712 holding.
STRS Ohio first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 12 quarters since.
STRS Ohio's CRISPR Therapeutics position peaked at $1.88M in Q2 2021.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.